[A17-28] Pembrolizumab (non-small cell lung cancer) - Addendum to Commission A17-06

Last updated 04.08.2017

Project no.:
A17-28

Commission:
Commission awarded on 21.06.2017 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

First-line therapy in patients with metastasizing NSCLC with PD-L1 expressing tumours and without activating EGFR or ALK mutation

Result of dossier assessment:

Unchanged hint of considerable added benefit

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

2017-08-03 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.